Bot Detector
Download FREE Sample Issue or Article
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy

Author(s):  Glaser Rebecca L, York Anne E

Issue:  Jul/Aug 2019 - Volume 23, Number 4
View All Articles in Issue

Page(s):  325-339

Note:  Electronic version includes supplemental material.

Download in electronic PDF format for $65

Abstract:  This analysis was designed to determine the efficacy of anastrozole, an aromatase inhibitor, combined with testosterone in a subcutaneous implant in preventing elevated estradiol levels and the subsequent side effects of excess estrogen associated with testosterone therapy. It also allowed for the establishment of normative ranges of serum testosterone levels on subcutaneous implant therapy. The study participants were 344 men who were accrued to an institutional review board-approved cohort study between April 2014 and 2017. Efficacy of the subcutaneous combination implant in maintaining low estradiol levels was evaluated. Serum levels of testosterone and estradiol were measured throughout the implant cycle, at week 4, and when symptoms returned. Correlations between patient demographics, dosing, and serum levels on therapy were evaluated. Mean testosterone dose was 1827 ± 262 mg. Mean anastrozole dose was 15.3 ± 3.2 mg with the majority of men receiving 16 mg of subcutaneous anastrozole. The mean interval of insertion was 4.8 months. Low estradiol levels were maintained throughout the implant cycle. Mean T level at week 4 was 1183 ± 315 ng/dl and 553 ± 239 ng/dl when symptoms returned. Levels of testosterone on therapy inversely correlated with body mass index. There were no adverse events attributed to testosterone or anastrozole therapy. Subcutaneous anastrozole delivered simultaneously with testosterone allowed for higher dosing of testosterone and less frequent intervals of insertion. Low-dose anastrozole released from the combination implant maintained low estradiol levels throughout the implant cycle and prevented clinical side effects attributed to excess estrogen.

Related Keywords: Rebecca L. Glaser, MD, Anne E. York, MS, anastrozole, aromatase inhibitor, testosterone, high-dose testosterone, subcutaneous implant, estradiol level, adverse effects, estrogen level, clinical study, men


Printer-Friendly Version

Related Articles from IJPC
(Click for Abstract / Details / Purchase)
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy
Glaser Rebecca L
, York Anne E
Jul/Aug 2019
Pg. 325-339

Poster Presentation Report: Safety of Maternal Testosterone Therapy During Breast Feeding
Glaser Rebecca L
, Newman Mark, Parsons Melanie, Zava David, Glaser-Garbrick Daniel
Jul/Aug 2009
Pg. 314-317

Testosterone Levels in an Aging Population: Screen, Measure, and Restore
Kells John
, DollbaumCharles M
Mar/Apr 2011
Pg. 102-112

Andropause: New Perspectives
Biundo Bruce
May/Jun 2004
Pg. 175-178

Basics of Compounding: Clinical Studies
Allen Loyd V Jr
Nov/Dec 2002
Pg. 443-447

Testosterone Deficiency in Men: New Treatments for Andropause
Biundo Bruce
, Shippen Eugene
Nov/Dec 2000
Pg. 429-431

Compounded Testosterone Troches to optimize Health and the Testosterone Controversy
Guth Michael AS
May/Jun 2015
Pg. 195-203

Case Study: Absorption of Testosterone Cream via Scrotal Delivery
Needham Shawn
, Needham Shane
Nov/Dec 2018
Pg. 466-468

Compounded Testosterone Gels: A Guide for Clinicians and Pharmacists
Cutter Christopher B
Nov/Dec 2000
Pg. 432-437

View Sample
Quantitation of Testosterone Propionate in an Injection Using High Performance Liquid Chromatography
Gupta Vishnu D
Mar/Apr 1999
Pg. 158-159

Particle Measuring Systems - USP <797> Environmental Monitoring Solutions